Alnylam AssistTM Can Support Your Patients

Alnylam AssistTM provides personalized support for patients throughout treatment with ONPATTRO® (patisiran).

Get Started

Hi, I’m Laura

Call me: 1-833-256-2748

Monday - Friday, 8am - 7pm ET

How Alnylam AssistTM Can Help

Alnylam AssistTM offers a wide range of services to guide your patients through treatment with ONPATTRO.


Benefit Verification

Help determining
patient-specific coverage


Financial Assistance

Information about patients'
eligibility for financial assistance


Patient Education

Disease and product education
for patients and families


Reimbursement Support

Education about the prior authorization,
claims, and appeals processes


Forms and Documents

Download the materials below for more information about Alnylam AssistTM.

Alnylam AssistTM Services Overview Brochure (PDF)

HCP Brochure


Alnylam AssistTM Brochure (PDF)

Patient Brochure



Enroll Your Patients

PhoneCall: 1-833-256-2748 Monday - Friday, 8am - 7pm (ET)

Begin the conversation with our team and help your patients join Alnylam AssistTM today.

Take Action Now1

Take Action Now

Together with your patient (in office)

Initiate then send to patient (over email)

Important Safety Information

Infusion-Related Reactions

Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO® (patisiran). In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.

To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed. 

Reduced Serum Vitamin A Levels and Recommended Supplementation

ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion-related reactions (19%).


ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about ONPATTRO, please see the full Prescribing Information.